Micronized Tecovirimat Rehydration for Polymorphic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for orthopoxvirus infections, such as smallpox and monkeypox, face challenges including poor bioavailability, toxicity, and resistance issues with existing antiviral compounds like cidofovir, and vaccination has adverse effects and limited protection against recombinant strains.
Innovation Solution
Development of a stable micronized monohydrate form of Tecovirimat (ST-246) through a rehydration process after micronization using air jet milling, which maintains pharmaceutical properties like stability and bioavailability by converting dehydrated particles back to monohydrate Form I, preventing conversion to less stable hemihydrate Form V.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If Tecovirimat monohydrate is micronized using air jet milling to improve bioavailability, then particle size is reduced and bioavailability improves, but the monohydrate converts to dehydrated anhydrous form which is less stable
Solution Approach 1:
The patent applies preliminary action by rehydrating the micronized Tecovirimat particles immediately after air jet milling to convert them back to the monohydrate form before storage. This prevents the dehydrated anhydrous form from being stored, thereby maintaining polymorphic stability while preserving the bioavailability benefits of micronization. The rehydration step is performed as a preliminary action prior to final product storage.
2Reliability
If existing antiviral compounds like cidofovir are used to treat orthopoxvirus infections, then antiviral activity is achieved, but poor bioavailability and toxicity issues arise
Solution Approach 1:
The patent applies parameter changes by modifying the physical parameters of Tecovirimat through micronization (reducing particle size) and controlling hydration state (maintaining monohydrate form). These parameter changes improve bioavailability while maintaining antiviral activity, offering a better safety profile compared to cidofovir.
3Reliability
If smallpox vaccination is used to prevent orthopoxvirus disease, then protective immunity is achieved, but adverse effects occur and protection against recombinant strains is limited
Solution Approach 1:
The patent applies the taking out principle by extracting the protective function from vaccination and providing it through a small molecule therapeutic alternative (Tecovirimat). This extracts the beneficial antiviral protection while eliminating the adverse effects associated with live virus vaccination, including risks to immunocompromised individuals and limited protection against recombinant strains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process ensures consistent production of stable micronized ST-246 monohydrate with improved bioavailability and shelf-life, addressing the limitations of existing antiviral therapies by maintaining stability and preventing conversion to less stable forms during storage.
Implementation Method 1
micronizing ST-246 using an air jet mill in order to reduce particle size
Implementation Method 2
micronizing ST-246 using an air jet mill in order to reduce particle size
Implementation Method 3
exposing said particles to moisture by conveying volumes of air containing moisture to said particles
Data Source
AI summary
Disclosed are methods for hydration of ST-246 particles comprising exposing said particles to moisture by conveying volumes of air containing moisture.